Masimo Co. (NASDAQ:MASI) Stake Reduced by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC reduced its stake in shares of Masimo Co. (NASDAQ:MASI) by 1.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 23,474 shares of the medical equipment provider’s stock after selling 391 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Masimo were worth $3,880,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Proficio Capital Partners LLC bought a new position in Masimo during the 4th quarter worth $7,733,000. Oppenheimer Asset Management Inc. grew its stake in shares of Masimo by 27.5% in the fourth quarter. Oppenheimer Asset Management Inc. now owns 4,568 shares of the medical equipment provider’s stock worth $755,000 after purchasing an additional 984 shares in the last quarter. Oregon Public Employees Retirement Fund grew its stake in shares of Masimo by 1.3% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 9,079 shares of the medical equipment provider’s stock worth $1,501,000 after purchasing an additional 113 shares in the last quarter. Sigma Planning Corp grew its stake in shares of Masimo by 21.7% in the fourth quarter. Sigma Planning Corp now owns 3,365 shares of the medical equipment provider’s stock worth $556,000 after purchasing an additional 600 shares in the last quarter. Finally, Navellier & Associates Inc. bought a new position in shares of Masimo in the fourth quarter worth $1,043,000. 85.96% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. Raymond James increased their price target on Masimo from $170.00 to $194.00 and gave the stock an “outperform” rating in a research note on Friday, December 27th. Stifel Nicolaus reissued a “buy” rating and issued a $190.00 price target (up previously from $170.00) on shares of Masimo in a research note on Friday, November 22nd. Needham & Company LLC reissued a “hold” rating on shares of Masimo in a research note on Wednesday, February 26th. Piper Sandler increased their price target on Masimo from $210.00 to $215.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 26th. Finally, Wells Fargo & Company upped their price objective on Masimo from $193.00 to $205.00 and gave the company an “overweight” rating in a report on Wednesday, February 26th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, Masimo currently has a consensus rating of “Moderate Buy” and a consensus target price of $194.80.

Masimo Trading Up 1.5 %

Shares of Masimo stock opened at $186.19 on Thursday. The company has a quick ratio of 1.11, a current ratio of 2.01 and a debt-to-equity ratio of 0.50. The firm has a market cap of $10.04 billion, a price-to-earnings ratio of 128.41 and a beta of 1.02. The business has a fifty day simple moving average of $174.79 and a 200-day simple moving average of $155.27. Masimo Co. has a fifty-two week low of $101.61 and a fifty-two week high of $194.88.

Masimo (NASDAQ:MASI) last announced its earnings results on Tuesday, February 25th. The medical equipment provider reported $1.80 EPS for the quarter, beating the consensus estimate of $1.42 by $0.38. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The business had revenue of $600.70 million during the quarter, compared to the consensus estimate of $593.35 million. On average, equities analysts forecast that Masimo Co. will post 4.1 EPS for the current fiscal year.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.